The therapeutic potential of mesenchymal stem cells in COVID-19: Present and future

Q3 Pharmacology, Toxicology and Pharmaceutics
M. I. Sari, I. Putra, D. W. Wijaya
{"title":"The therapeutic potential of mesenchymal stem cells in COVID-19: Present and future","authors":"M. I. Sari, I. Putra, D. W. Wijaya","doi":"10.18413/rrpharmacology.9.10031","DOIUrl":null,"url":null,"abstract":"Introduction: Coronavirus disease 2019 (COVID-19) was first reported in 2019 and has since become a health concern due to its rapid spread and high mortality rate. With the discovery of vaccines, there has been a reduction in disease occurrence, transmission, mortality, and morbidity in a population. However, with the emergence of newvariants, the available vaccines show varying efficiencies depending on the population and variants, while the present drugs may lose their effectiveness, hence the urgent need to explore effective therapies. Mesenchymal stemcells (MSCs) have been widely studied for their anti-inflammatory and immunomodulatory effects as COVID-19treatment and shown their potential to improve the condition of COVID-19 patients. This systematic review aims to assess the therapeutic potential of MSCs as anti-inflammatory and immunomodulatory agent in COVID-19.\nMaterials and Methods: A literature search is performed on PubMed, ScienceDirect, ProQuest, and Google Scholar and potentially relevant studies to review, based on the inclusion and exclusion criteria we have determined.We identified 14,090  publications from our search and excluded duplicates as well as irrelevant studies from title,abstract, and full-text screening. Data extraction and analysis were then performed in the 20 eligible studies.\nResults and Discussion: Results show that MSCs improve immune system dysregulation throughimmunomodulatory and anti-inflammatory effects, through reducing blood C-reactive protein (CRP) and IL-6 levels.\nConclusion: We conclude that MSC is one of the promising treatments in COVID-19 regardless of variants.\nGraphical Abstract","PeriodicalId":21030,"journal":{"name":"Research Results in Pharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research Results in Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18413/rrpharmacology.9.10031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) was first reported in 2019 and has since become a health concern due to its rapid spread and high mortality rate. With the discovery of vaccines, there has been a reduction in disease occurrence, transmission, mortality, and morbidity in a population. However, with the emergence of newvariants, the available vaccines show varying efficiencies depending on the population and variants, while the present drugs may lose their effectiveness, hence the urgent need to explore effective therapies. Mesenchymal stemcells (MSCs) have been widely studied for their anti-inflammatory and immunomodulatory effects as COVID-19treatment and shown their potential to improve the condition of COVID-19 patients. This systematic review aims to assess the therapeutic potential of MSCs as anti-inflammatory and immunomodulatory agent in COVID-19. Materials and Methods: A literature search is performed on PubMed, ScienceDirect, ProQuest, and Google Scholar and potentially relevant studies to review, based on the inclusion and exclusion criteria we have determined.We identified 14,090  publications from our search and excluded duplicates as well as irrelevant studies from title,abstract, and full-text screening. Data extraction and analysis were then performed in the 20 eligible studies. Results and Discussion: Results show that MSCs improve immune system dysregulation throughimmunomodulatory and anti-inflammatory effects, through reducing blood C-reactive protein (CRP) and IL-6 levels. Conclusion: We conclude that MSC is one of the promising treatments in COVID-19 regardless of variants. Graphical Abstract
间充质干细胞在COVID-19中的治疗潜力:现在和未来
2019冠状病毒病(COVID-19)于2019年首次报道,由于其迅速传播和高死亡率,已成为一个健康问题。随着疫苗的发现,人群中疾病的发生、传播、死亡率和发病率都有所减少。然而,随着新变种的出现,现有疫苗根据人群和变种表现出不同的效率,而现有药物可能会失去效力,因此迫切需要探索有效的治疗方法。间充质干细胞(MSCs)因其抗炎和免疫调节作用而被广泛研究,并显示出其改善COVID-19患者病情的潜力。本系统综述旨在评估MSCs作为抗炎和免疫调节剂在COVID-19中的治疗潜力。材料和方法:根据我们确定的纳入和排除标准,在PubMed、ScienceDirect、ProQuest和谷歌Scholar上进行文献检索和潜在的相关研究进行审查。我们从搜索中确定了14090篇出版物,并从标题、摘要和全文筛选中排除了重复和不相关的研究。然后对20项符合条件的研究进行数据提取和分析。结果与讨论:结果表明MSCs通过降低血液c -反应蛋白(CRP)和IL-6水平,通过免疫调节和抗炎作用改善免疫系统失调。结论:我们认为MSC是治疗COVID-19的有希望的治疗方法之一。图形抽象
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Research Results in Pharmacology
Research Results in Pharmacology Medicine-Pharmacology (medical)
CiteScore
1.50
自引率
0.00%
发文量
32
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信